Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells

Tewodros Mamo, Ann C. Mladek, Kris L. Shogren, Carl Gustafson, Shiv K. Gupta, Scott M. Riester, Avudaiappan Maran, Mario Galindo, Andre J van Wijnen, Jann N Sarkaria, Michael J Yaszemski

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Osteosarcoma survival rate has not improved over the past three decades, and the debilitating side effects of the surgical treatment suggest the need for alternative local control approaches. Radiotherapy is largely ineffective in osteosarcoma, indicating a potential role for radiosensitizers. Blocking DNA repair, particularly by inhibiting the catalytic subunit of DNA-dependent protein kinase (DNA-PKCS), is an attractive option for the radiosensitization of osteosarcoma. In this study, the expression of DNA-PKCS in osteosarcoma tissue specimens and cell lines was examined. Moreover, the small molecule DNA-PKCS inhibitor, KU60648, was investigated as a radiosensitizing strategy for osteosarcoma cells in vitro. DNA-PKCS was consistently expressed in the osteosarcoma tissue specimens and cell lines studied. Additionally, KU60648 effectively sensitized two of those osteosarcoma cell lines (143B cells by 1.5-fold and U2OS cells by 2.5-fold). KU60648 co-treatment also altered cell cycle distribution and enhanced DNA damage. Cell accumulation at the G2/M transition point increased by 55% and 45%, while the percentage of cells with >20 γH2AX foci were enhanced by 59% and 107% for 143B and U2OS cells, respectively. These results indicate that the DNA-PKCS inhibitor, KU60648, is a promising radiosensitizing agent for osteosarcoma.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume486
Issue number2
DOIs
StatePublished - Apr 29 2017

Fingerprint

lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine
Osteosarcoma
DNA
Cells
Cell Line
DNA-Activated Protein Kinase
Tissue
Radiation-Sensitizing Agents
Catalytic DNA
Radiotherapy

Keywords

  • DNA-PK
  • DNA-PKcs
  • KU60648
  • Osteosarcoma
  • Radiosensitizers
  • Radiotherapy

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells. / Mamo, Tewodros; Mladek, Ann C.; Shogren, Kris L.; Gustafson, Carl; Gupta, Shiv K.; Riester, Scott M.; Maran, Avudaiappan; Galindo, Mario; van Wijnen, Andre J; Sarkaria, Jann N; Yaszemski, Michael J.

In: Biochemical and Biophysical Research Communications, Vol. 486, No. 2, 29.04.2017, p. 307-313.

Research output: Contribution to journalArticle

Mamo, T, Mladek, AC, Shogren, KL, Gustafson, C, Gupta, SK, Riester, SM, Maran, A, Galindo, M, van Wijnen, AJ, Sarkaria, JN & Yaszemski, MJ 2017, 'Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells', Biochemical and Biophysical Research Communications, vol. 486, no. 2, pp. 307-313. https://doi.org/10.1016/j.bbrc.2017.03.033
Mamo T, Mladek AC, Shogren KL, Gustafson C, Gupta SK, Riester SM et al. Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells. Biochemical and Biophysical Research Communications. 2017 Apr 29;486(2):307-313. https://doi.org/10.1016/j.bbrc.2017.03.033
Mamo, Tewodros ; Mladek, Ann C. ; Shogren, Kris L. ; Gustafson, Carl ; Gupta, Shiv K. ; Riester, Scott M. ; Maran, Avudaiappan ; Galindo, Mario ; van Wijnen, Andre J ; Sarkaria, Jann N ; Yaszemski, Michael J. / Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells. In: Biochemical and Biophysical Research Communications. 2017 ; Vol. 486, No. 2. pp. 307-313.
@article{973385719c354ca59fb46cd4c0bac55d,
title = "Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells",
abstract = "Osteosarcoma survival rate has not improved over the past three decades, and the debilitating side effects of the surgical treatment suggest the need for alternative local control approaches. Radiotherapy is largely ineffective in osteosarcoma, indicating a potential role for radiosensitizers. Blocking DNA repair, particularly by inhibiting the catalytic subunit of DNA-dependent protein kinase (DNA-PKCS), is an attractive option for the radiosensitization of osteosarcoma. In this study, the expression of DNA-PKCS in osteosarcoma tissue specimens and cell lines was examined. Moreover, the small molecule DNA-PKCS inhibitor, KU60648, was investigated as a radiosensitizing strategy for osteosarcoma cells in vitro. DNA-PKCS was consistently expressed in the osteosarcoma tissue specimens and cell lines studied. Additionally, KU60648 effectively sensitized two of those osteosarcoma cell lines (143B cells by 1.5-fold and U2OS cells by 2.5-fold). KU60648 co-treatment also altered cell cycle distribution and enhanced DNA damage. Cell accumulation at the G2/M transition point increased by 55{\%} and 45{\%}, while the percentage of cells with >20 γH2AX foci were enhanced by 59{\%} and 107{\%} for 143B and U2OS cells, respectively. These results indicate that the DNA-PKCS inhibitor, KU60648, is a promising radiosensitizing agent for osteosarcoma.",
keywords = "DNA-PK, DNA-PKcs, KU60648, Osteosarcoma, Radiosensitizers, Radiotherapy",
author = "Tewodros Mamo and Mladek, {Ann C.} and Shogren, {Kris L.} and Carl Gustafson and Gupta, {Shiv K.} and Riester, {Scott M.} and Avudaiappan Maran and Mario Galindo and {van Wijnen}, {Andre J} and Sarkaria, {Jann N} and Yaszemski, {Michael J}",
year = "2017",
month = "4",
day = "29",
doi = "10.1016/j.bbrc.2017.03.033",
language = "English (US)",
volume = "486",
pages = "307--313",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells

AU - Mamo, Tewodros

AU - Mladek, Ann C.

AU - Shogren, Kris L.

AU - Gustafson, Carl

AU - Gupta, Shiv K.

AU - Riester, Scott M.

AU - Maran, Avudaiappan

AU - Galindo, Mario

AU - van Wijnen, Andre J

AU - Sarkaria, Jann N

AU - Yaszemski, Michael J

PY - 2017/4/29

Y1 - 2017/4/29

N2 - Osteosarcoma survival rate has not improved over the past three decades, and the debilitating side effects of the surgical treatment suggest the need for alternative local control approaches. Radiotherapy is largely ineffective in osteosarcoma, indicating a potential role for radiosensitizers. Blocking DNA repair, particularly by inhibiting the catalytic subunit of DNA-dependent protein kinase (DNA-PKCS), is an attractive option for the radiosensitization of osteosarcoma. In this study, the expression of DNA-PKCS in osteosarcoma tissue specimens and cell lines was examined. Moreover, the small molecule DNA-PKCS inhibitor, KU60648, was investigated as a radiosensitizing strategy for osteosarcoma cells in vitro. DNA-PKCS was consistently expressed in the osteosarcoma tissue specimens and cell lines studied. Additionally, KU60648 effectively sensitized two of those osteosarcoma cell lines (143B cells by 1.5-fold and U2OS cells by 2.5-fold). KU60648 co-treatment also altered cell cycle distribution and enhanced DNA damage. Cell accumulation at the G2/M transition point increased by 55% and 45%, while the percentage of cells with >20 γH2AX foci were enhanced by 59% and 107% for 143B and U2OS cells, respectively. These results indicate that the DNA-PKCS inhibitor, KU60648, is a promising radiosensitizing agent for osteosarcoma.

AB - Osteosarcoma survival rate has not improved over the past three decades, and the debilitating side effects of the surgical treatment suggest the need for alternative local control approaches. Radiotherapy is largely ineffective in osteosarcoma, indicating a potential role for radiosensitizers. Blocking DNA repair, particularly by inhibiting the catalytic subunit of DNA-dependent protein kinase (DNA-PKCS), is an attractive option for the radiosensitization of osteosarcoma. In this study, the expression of DNA-PKCS in osteosarcoma tissue specimens and cell lines was examined. Moreover, the small molecule DNA-PKCS inhibitor, KU60648, was investigated as a radiosensitizing strategy for osteosarcoma cells in vitro. DNA-PKCS was consistently expressed in the osteosarcoma tissue specimens and cell lines studied. Additionally, KU60648 effectively sensitized two of those osteosarcoma cell lines (143B cells by 1.5-fold and U2OS cells by 2.5-fold). KU60648 co-treatment also altered cell cycle distribution and enhanced DNA damage. Cell accumulation at the G2/M transition point increased by 55% and 45%, while the percentage of cells with >20 γH2AX foci were enhanced by 59% and 107% for 143B and U2OS cells, respectively. These results indicate that the DNA-PKCS inhibitor, KU60648, is a promising radiosensitizing agent for osteosarcoma.

KW - DNA-PK

KW - DNA-PKcs

KW - KU60648

KW - Osteosarcoma

KW - Radiosensitizers

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85015934015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015934015&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2017.03.033

DO - 10.1016/j.bbrc.2017.03.033

M3 - Article

C2 - 28300555

AN - SCOPUS:85015934015

VL - 486

SP - 307

EP - 313

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -